These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. Jick H; Vasilakis C; Weinrauch LA; Meier CR; Jick SS; Derby LE N Engl J Med; 1998 Sep; 339(11):719-24. PubMed ID: 9731087 [TBL] [Abstract][Full Text] [Related]
7. [The French are wary of their drugs]. Nau JY Rev Med Suisse; 2011 May; 7(296):1170-1. PubMed ID: 21728251 [No Abstract] [Full Text] [Related]
8. Temporal trends and drug exposures in pulmonary hypertension: an American experience. Walker AM; Langleben D; Korelitz JJ; Rich S; Rubin LJ; Strom BL; Gonin R; Keast S; Badesch D; Barst RJ; Bourge RC; Channick R; Frost A; Gaine S; McGoon M; McLaughlin V; Murali S; Oudiz RJ; Robbins IM; Tapson V; Abenhaim L; Constantine G Am Heart J; 2006 Sep; 152(3):521-6. PubMed ID: 16923424 [TBL] [Abstract][Full Text] [Related]
9. Primary pulmonary hypertension and long-term use of appetite suppressants. Sztuke-Fournier A CMAJ; 1997 Jan; 156(1):89-90, 93-4. PubMed ID: 9006574 [No Abstract] [Full Text] [Related]
10. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. Abenhaim L; Moride Y; Brenot F; Rich S; Benichou J; Kurz X; Higenbottam T; Oakley C; Wouters E; Aubier M; Simonneau G; Bégaud B N Engl J Med; 1996 Aug; 335(9):609-16. PubMed ID: 8692238 [TBL] [Abstract][Full Text] [Related]
11. Appetite-suppressant drugs and the risk of primary pulmonary hypertension? Deitel M Obes Surg; 1997 Feb; 7(1):3-4. PubMed ID: 9730529 [No Abstract] [Full Text] [Related]
12. Valvular heart disease associated with benfluorex therapy: results from the French multicentre registry. Le Ven F; Tribouilloy C; Habib G; Gueffet JP; Maréchaux S; Eicher JC; Blanchard-Lemoine B; Rousseau J; Hénon P; Jobic Y; Etienne Y Eur J Echocardiogr; 2011 Apr; 12(4):265-71. PubMed ID: 21193484 [TBL] [Abstract][Full Text] [Related]
13. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Simonneau G; Fartoukh M; Sitbon O; Humbert M; Jagot JL; Hervé P Chest; 1998 Sep; 114(3 Suppl):195S-199S. PubMed ID: 9741568 [TBL] [Abstract][Full Text] [Related]
14. Autopsy findings of heart and lungs in a patient with primary pulmonary hypertension associated with use of fenfluramine and phentermine. Tomita T; Zhao Q Chest; 2002 Feb; 121(2):649-52. PubMed ID: 11834685 [TBL] [Abstract][Full Text] [Related]
15. High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium. Delcroix M; Kurz X; Walckiers D; Demedts M; Naeije R Eur Respir J; 1998 Aug; 12(2):271-6. PubMed ID: 9727773 [TBL] [Abstract][Full Text] [Related]
16. [Female gender and pulmonary arterial hypertension: a complex relationship]. Manes A; Palazzini M; Dardi F; D'Adamo A; Rinaldi A; Galiè N G Ital Cardiol (Rome); 2012 Jun; 13(6):448-60. PubMed ID: 22622125 [TBL] [Abstract][Full Text] [Related]
17. Fenfluramines, idiopathic pulmonary primary hypertension and cardiac valve disorders: facts and artifacts. Tellier P Ann Med Interne (Paris); 2001 Nov; 152(7):429-36. PubMed ID: 11965083 [TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Sztrymf B; Coulet F; Girerd B; Yaici A; Jais X; Sitbon O; Montani D; Souza R; Simonneau G; Soubrier F; Humbert M Am J Respir Crit Care Med; 2008 Jun; 177(12):1377-83. PubMed ID: 18356561 [TBL] [Abstract][Full Text] [Related]
20. Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population. Schoonjans AS; Marchau F; Paelinck BP; Lagae L; Gammaitoni A; Pringsheim M; Keane MG; Ceulemans B Curr Med Res Opin; 2017 Oct; 33(10):1773-1781. PubMed ID: 28704161 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]